Drug Trial Radar · NCT02949011
Study of S-033188 (Baloxavir Marboxil) Compared With Placebo or Oseltamivir in Patients With Influenza at High Risk of Influenza Complications
Last checked: Nov 20, 2026Latest source record: Nov 19, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
2,184
Actual
Start
Jan 11, 2017
Primary completion
Apr 12, 2018
Study completion Apr 20, 2018
Sponsor
- Lead sponsor
- ShionogiIndustry
- Sponsor type
- Industry
- First posted
- Oct 31, 2016
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 12 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of this study is to evaluate the efficacy of a single, oral dose of baloxavir marboxil compared with placebo by measuring the time to improvement of influenza symptoms in patients with influenza presenting within 48 hours of symptom onset.
Conditions
- Influenza
Interventions
Baloxavir MarboxilDrug
Tablets taken orally
Placebo to Baloxavir MarboxilDrug
Matching tablets taken orally
OseltamivirDrug
Capsules taken orally
Placebo to OseltamivirDrug
Matching placebo capsules taken orally
Primary outcomes
What the sponsor says the trial is designed to measure.
- Time to Improvement of Influenza SymptomsTime frame: From Day 1 pretreatment up to Day 14
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.